Renalytix Plc (RNLXY)

OTCMKTS · Delayed Price · Currency is USD
0.240
-0.023 (-8.75%)
Feb 21, 2025, 4:00 PM EST
99.83%
Market Cap 48.15M
Revenue (ttm) 2.35M
Net Income (ttm) -28.03M
Shares Out n/a
EPS (ttm) -0.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,703
Average Volume 40,700
Open 0.240
Previous Close 0.263
Day's Range 0.240 - 0.240
52-Week Range 0.120 - 1.770
Beta n/a
RSI 46.39
Earnings Date Feb 18, 2025

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, pa... [Read more]

Sector Healthcare
Founded 2018
Employees 102
Stock Exchange OTCMKTS
Ticker Symbol RNLXY
Full Company Profile

Financial Performance

In 2024, Renalytix's revenue was $2.29 million, a decrease of -32.74% compared to the previous year's $3.40 million. Losses were -$33.46 million, -26.64% less than in 2023.

Financial Statements

News

There is no news available yet.